Functionalized liposomes for colorectal cancer therapy

Colorectal cancer (CRC) is one of the most common cancers. Many patients do not live for several years following their diagnosis, highlighting the urgent need for new treatment options, including new drug delivery methods. An effective strategy to increase the effectiveness of the treatment ofthis cancer is the use of a liposomal deliverysystem, which provides the possibility of providing hydrophobic and hydrophilic compounds with better biocompatibility and reduction of side effects by using several advantages, thus causing anti-cancer activity. Better tumor, drug accumulation is longer and they do not show any cytotoxic effect on normal cells. In this review, we will present nanoliposomes containing various compounds and ligands studied in CRC treatment. We will discuss on the benefits of liposomal administration in various forms, along with their effectiveness, specificity, and drug accumulation. Nanoliposome carriers have enormous potential to overcome the present constraints of cancer treatment, and the creation of this technology gives new possibilities in CRC treatment.

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2024-12-20
DOI
https://doi.org/10.5281/zenodo.14534003
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Functionalized liposomes for colorectal cancer therapy

Zenodo (CERN European Organization for Nuclear Research)
Nanoparticle-Based Drug Delivery
article

Functionalized liposomes for colorectal cancer therapy

article en

Abstract

Colorectal cancer (CRC) is one of the most common cancers. Many patients do not live for several years following their diagnosis, highlighting the urgent need for new treatment options, including new drug delivery methods. An effective strategy to increase the effectiveness of the treatment ofthis cancer is the use of a liposomal deliverysystem, which provides the possibility of providing hydrophobic and hydrophilic compounds with better biocompatibility and reduction of side effects by using several advantages, thus causing anti-cancer activity. Better tumor, drug accumulation is longer and they do not show any cytotoxic effect on normal cells. In this review, we will present nanoliposomes containing various compounds and ligands studied in CRC treatment. We will discuss on the benefits of liposomal administration in various forms, along with their effectiveness, specificity, and drug accumulation. Nanoliposome carriers have enormous potential to overcome the present constraints of cancer treatment, and the creation of this technology gives new possibilities in CRC treatment.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 62%
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.